Novel Point-of-Care Diagnostic Method for Neonatal Encephalopathy Using Purine Nucleosides.

Tools

BEAMER, Edward, O'DEA, Mary Isabel, GARVEY, Aisling A, SMITH, Jonathon, MENÉNDEZ-MÉNDEZ, Aida, KELLY, Lynne, PAVEL, Andreea, QUINLAN, Sean, ALVES, Mariana, JIMENEZ-MATEOS, Eva M, TIAN, Faming, DEMPSEY, Eugene, DALE, Nicholas, MURRAY, Deirdre M, BOYLAN, Geraldine B, MOLLOY, Eleanor J and ENGEL, Tobias (2021). Novel Point-of-Care Diagnostic Method for Neonatal Encephalopathy Using Purine Nucleosides. Frontiers in molecular neuroscience, 14: 732199. [Article]

Documents
35331:990472
[thumbnail of Beamer-NovelPointOfCare(VoR).pdf]
Preview
PDF
Beamer-NovelPointOfCare(VoR).pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
Abstract
Background: Evidence suggests that earlier diagnosis and initiation of treatment immediately after birth is critical for improved neurodevelopmental outcomes following neonatal encephalopathy (NE). Current diagnostic tests are, however, mainly restricted to clinical diagnosis with no molecular tests available. Purines including adenosine are released during brain injury such as hypoxia and are also present in biofluids. Whether blood purine changes can be used to diagnose NE has not been investigated to date. Methods: Blood purines were measured in a mouse model of neonatal hypoxia and infants with NE using a novel point-of-care diagnostic technology (SMARTChip) based on the summated electrochemical detection of adenosine and adenosine metabolites in the blood. Results: Blood purine concentrations were ∼2-3-fold elevated following hypoxia in mice [2.77 ± 0.48 μM (Control) vs. 7.57 ± 1.41 μM (post-hypoxia), p = 0.029]. Data in infants with NE had a 2-3-fold elevation when compared to healthy controls [1.63 ± 0.47 μM (Control, N = 5) vs. 4.87 ± 0.92 μM (NE, N = 21), p = 0.0155]. ROC curve analysis demonstrates a high sensitivity (81%) and specificity (80%) for our approach to identify infants with NE. Moreover, blood purine concentrations were higher in infants with NE and seizures [8.13 ± 3.23 μM (with seizures, N = 5) vs. 3.86 ± 0.56 μM (without seizures, N = 16), p = 0.044]. Conclusion: Our data provides the proof-of-concept that measurement of blood purine concentrations via SMARTChip technology may offer a low-volume bedside test to support a rapid diagnosis of NE.
More Information
Official URL:
https://doi.org/10.3389/fnmol.2021.732199
Uncontrolled Keywords:
neonatal encephalopathy; biomarker; purines; mouse models; clinical testing; seizures; biomarker; clinical testing; mouse models; neonatal encephalopathy; purines; seizures; 1103 Clinical Sciences; 1109 Neurosciences; 3101 Biochemistry and cell biology; 3209 Neurosciences; 5202 Biological psychology
Event Location:
Switzerland

Identifiers

Identification Number:
10.3389/fnmol.2021.732199
ORCID for Edward Beamer: ORCID iD orcid.org/0000-0003-1947-7346
ORCID for Jonathon Smith: ORCID iD orcid.org/0000-0003-3379-7311
ORCID for Lynne Kelly: ORCID iD orcid.org/0000-0002-4782-1143
ORCID for Eva M Jimenez-Mateos: ORCID iD orcid.org/0000-0001-6417-6580
ORCID for Eugene Dempsey: ORCID iD orcid.org/0000-0002-6266-3462
ORCID for Geraldine B Boylan: ORCID iD orcid.org/0000-0003-0920-5291
ORCID for Eleanor J Molloy: ORCID iD orcid.org/0000-0001-6798-2158

Library

Item Type:
Article
SWORD Depositor:
Symplectic Elements
Depositing User:
Symplectic Elements
Date record made live:
22 Jul 2025 15:33
Last Modified:
22 Jul 2025 15:45
Date of first compliant deposit:
22 July 2025
Date of first compliant Open Access:
22 July 2025
Version of first compliant deposit:
Version of Record
URI:
https://shura.shu.ac.uk/id/eprint/35331
Statistics

Downloads

Downloads per month over past year

View more statistics

Metrics

Altmetric Badge

Dimensions Badge

Share
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Actions (login required)

View Item View Item

SHURA supports OAI 2.0 with a base URL of https://shura.shu.ac.uk/cgi/oai2